Pharmacopeia Identifies Lead Compound for Bristol-Myers Squibb

Dec 18, 1998

Premium

PRINCETON, NJ--Pharmacopeia reached a milestone in its collaboration with Bristol-Myers Squibb on inflammatory and immunological disease targets when it identified a lead compound, the company announced last week. Bristol-Myers made a cash payment to Pharmacopeia for the achievement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Who Are You?

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

'Problematic'

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Republicans Take on Peer Review

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

This Week in Science

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Main menu